Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Pariser

Showing results (31-40 of 62) with videos related to

Pageof 7
Sort By:
Aesthetic Surgery Journal|November 26, 2024
NivobotulinumtoxinA in the Treatment of Glabellar Lines With or Without Concurrent Treatment of Lateral Canthal Lines in Two Phase 3 Clinical TrialsWilliam Coleman, Vince Bertucci, Shannon Humphrey, et al.
Journal of Drugs in Dermatology : JDD|May 19, 2005
Clobetasol propionate 0.05% lotion in the treatment of moderate to severe atopic dermatitis: a randomized evaluation versus clobetasol propionate emollient creamDebra Breneman, Alan B Fleischer, David Kaplan, et al.
Journal of Drugs in Dermatology : JDD|June 5, 2023
Integrating Precision Medicine into Medical Dermatology Clinical Practice: An Expert Consensus PanelDanny Zakria, Nicholas Brownstone, April W Armstrong, et al.
Journal of Drugs in Dermatology : JDD|March 17, 2017
Two Multicenter, Randomized, Double-Blind, Parallel Group Comparison Studies of a Novel Enhanced Lotion Formulation of Halobetasol Propionate, 0.05% Versus Its Vehicle in Adult Subjects With Plaque PsoriasisDavid Pariser, Michael Bukhalo, Scott Guenthner, et al.
Journal of the American Academy of Dermatology|September 25, 2004
A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitisSteven Kempers, Mark Boguniewicz, Eric Carter, et al.
Journal of the American Academy of Dermatology|April 22, 2018
Introducing a curriculum in ethics and professionalism for dermatology residenciesBenjamin K Stoff, Jane M Grant-Kels, Robert T Brodell, et al.
Journal of the American Academy of Dermatology|January 14, 2015
WITHDRAWN: Experience with ustekinumab in patients with psoriasis enrolled in a large, multicenter, prospective, disease-based registry (Psoriasis Longitudinal Assessment and Registry [PSOLAR])Kim Papp, Alice B Gottlieb, Luigi Naldi, et al.
Journal of the American Academy of Dermatology|February 19, 2020
Efficacy and safety of topical sofpironium bromide gel for the treatment of axillary hyperhidrosis: A phase II, randomized, controlled, double-blinded trialBrandon Kirsch, Stacy Smith, Joel Cohen, et al.
Journal of Gerontological Social Work|March 25, 2009
Impact of geriatric assessment and self-management support on community-dwelling older adults with chronic illnessesAnna C Faul, Pamela A Yankeelov, Noell L Rowan, et al.
Journal of Drugs in Dermatology : JDD|July 8, 2015
Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)Kim Papp, Alice B Gottlieb, Luigi Naldi, et al.
Pageof 7

Showing results (31-40 of 62) with videos related to

Sort By:
Pageof 7
Aesthetic Surgery Journal|November 26, 2024
NivobotulinumtoxinA in the Treatment of Glabellar Lines With or Without Concurrent Treatment of Lateral Canthal Lines in Two Phase 3 Clinical TrialsWilliam Coleman, Vince Bertucci, Shannon Humphrey, et al.
Journal of Drugs in Dermatology : JDD|May 19, 2005
Clobetasol propionate 0.05% lotion in the treatment of moderate to severe atopic dermatitis: a randomized evaluation versus clobetasol propionate emollient creamDebra Breneman, Alan B Fleischer, David Kaplan, et al.
Journal of Drugs in Dermatology : JDD|June 5, 2023
Integrating Precision Medicine into Medical Dermatology Clinical Practice: An Expert Consensus PanelDanny Zakria, Nicholas Brownstone, April W Armstrong, et al.
Journal of Drugs in Dermatology : JDD|March 17, 2017
Two Multicenter, Randomized, Double-Blind, Parallel Group Comparison Studies of a Novel Enhanced Lotion Formulation of Halobetasol Propionate, 0.05% Versus Its Vehicle in Adult Subjects With Plaque PsoriasisDavid Pariser, Michael Bukhalo, Scott Guenthner, et al.
Journal of the American Academy of Dermatology|September 25, 2004
A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitisSteven Kempers, Mark Boguniewicz, Eric Carter, et al.
Journal of the American Academy of Dermatology|April 22, 2018
Introducing a curriculum in ethics and professionalism for dermatology residenciesBenjamin K Stoff, Jane M Grant-Kels, Robert T Brodell, et al.
Journal of the American Academy of Dermatology|January 14, 2015
WITHDRAWN: Experience with ustekinumab in patients with psoriasis enrolled in a large, multicenter, prospective, disease-based registry (Psoriasis Longitudinal Assessment and Registry [PSOLAR])Kim Papp, Alice B Gottlieb, Luigi Naldi, et al.
Journal of the American Academy of Dermatology|February 19, 2020
Efficacy and safety of topical sofpironium bromide gel for the treatment of axillary hyperhidrosis: A phase II, randomized, controlled, double-blinded trialBrandon Kirsch, Stacy Smith, Joel Cohen, et al.
Journal of Gerontological Social Work|March 25, 2009
Impact of geriatric assessment and self-management support on community-dwelling older adults with chronic illnessesAnna C Faul, Pamela A Yankeelov, Noell L Rowan, et al.
Journal of Drugs in Dermatology : JDD|July 8, 2015
Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)Kim Papp, Alice B Gottlieb, Luigi Naldi, et al.
Pageof 7